# Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT03058744** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 94 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** IDP-118 Lotion
- **DRUG:** HP Monad Lotion
- **DRUG:** Ultravate Cream
- **DRUG:** Tazorac Cream

## Key facts

- **NCT ID:** NCT03058744
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-12
- **Final completion:** 2017-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03058744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03058744, "Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03058744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*